4SC AG (Frankfurt, Prime Standard: VSC), a drug discovery and development company focused on autoimmune and cancer indications, has presented novel data on the mechanism of action of vidofludimus, an oral inhibitor of interleukin-17 (IL-17A and IL-17F) release and DHODH. These data show that vidofludimus inhibits STAT3 and NF-kB signaling pathways in murine colitis models and were presented at Digestive Disease Week, the world’s largest gastroenterology conference, held from May 7-10, 2011 in Chicago, USA. In addition, final results from the previously announced vidofludimus Phase IIa study in inflammatory bowel disease (the ‘ENTRANCE’ trial) were also presented.
